We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

134 hedge funds and large institutions have $245M invested in BioCryst Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 52 increasing their positions, 38 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

671% more call options, than puts

Call options by funds: $3.05M | Put options by funds: $396K

37% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 38

4% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 25

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1% less funds holding

Funds holding: 136 → 134 (-2)

9.59% less ownership

Funds ownership: 89.1% → 79.51% (-9.6%)

48% less capital invested

Capital invested by funds: $473M → $245M (-$228M)

Holders
134
Holders Change
-2
Holders Change %
-1.47%
% of All Funds
2.95%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
26
Increased
52
Reduced
38
Closed
25
Calls
$3.05M
Puts
$396K
Net Calls
+$2.66M
Net Calls Change
+$1.39M

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$9.64M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$8.28M
3
EP
Eversept Partners
New York
+$7.26M
4
Stifel Financial
Stifel Financial
Missouri
+$5.76M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.5M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$14.8M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$12.5M
3
Millennium Management
Millennium Management
New York
-$9.6M
4
PVI
Pura Vida Investments
New York
-$7.52M
5
ACP
Acuta Capital Partners
California
-$7.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCP
51
GSA Capital Partners
United Kingdom
$277K +$382K +138,664 New
New York State Common Retirement Fund
52
New York State Common Retirement Fund
New York
$266K – – –
VEA
53
Virtus ETF Advisers
New York
$242K -$48.6K -17,661 -13%
Los Angeles Capital Management
54
Los Angeles Capital Management
California
$238K +$83K +30,130 +34%
UBS AM
55
UBS AM
Illinois
$233K -$31.4K -11,387 -9%
Commonwealth Equity Services
56
Commonwealth Equity Services
Massachusetts
$199K +$41.1K +14,932 +18%
Manulife (Manufacturers Life Insurance)
57
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$196K +$75.2K +27,330 +39%
BBVA
58
Banco Bilbao Vizcaya Argentaria
Spain
$193K +$184K +66,800 +223%
Wells Fargo
59
Wells Fargo
California
$184K -$144K -52,306 -36%
AIG
60
American International Group
New York
$182K -$4.69K -1,703 -2%
Squarepoint
61
Squarepoint
New York
$175K -$1.46M -531,370 -86%
PCS
62
Personal CFO Solutions
New Jersey
$174K +$152K +55,078 +172%
CAM
63
ClariVest Asset Management
California
$169K +$233K +84,700 New
VOYA Investment Management
64
VOYA Investment Management
Georgia
$156K +$15.9K +5,772 +8%
FSA
65
Franklin Street Advisors
North Carolina
$150K +$68.8K +25,000 +50%
Marshall Wace
66
Marshall Wace
United Kingdom
$143K +$197K +71,660 New
BNP Paribas Financial Markets
67
BNP Paribas Financial Markets
France
$141K +$147K +53,338 +310%
SG Americas Securities
68
SG Americas Securities
New York
$125K +$116K +42,146 +209%
DMK
69
David M. Knott
$120K +$165K +59,990 New
State Board of Administration of Florida Retirement System
70
State Board of Administration of Florida Retirement System
Florida
$108K -$1.02K -370 -0.7%
Royal Bank of Canada
71
Royal Bank of Canada
Ontario, Canada
$102K +$125K +45,261 +791%
MLICM
72
Metropolitan Life Insurance Company (MetLife)
New York
$101K +$862 +313 +0.6%
Victory Capital Management
73
Victory Capital Management
Texas
$100K +$137K +49,638 New
PPA
74
Parametric Portfolio Associates
Washington
$99K +$49.1K +17,849 +57%
DTL
75
Dynamic Technology Lab
Singapore
$99K +$136K +49,335 New
1 2
3
4 5

BCRX Hedge Fund Activity: Q1 2020 in Review

134 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2020, worth a combined $245M — down 48% from $473M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new BCRX positions and 25 closed out — a net gain of 1 holder — while 52 added to existing stakes and 38 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $9.64M. The largest seller was Point72 Asset Management, cutting an estimated $14.8M.

  • 134 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2020, down from 136 in Q4 2019.
  • Funds reported $245M of BioCryst Pharmaceuticals stock for Q1 2020, down 48% quarter-over-quarter.
  • 26 funds opened new BioCryst Pharmaceuticals positions in Q1 2020 and 25 closed out, a net change of +1 holder.
  • The largest BioCryst Pharmaceuticals buyer in Q1 2020 was Adage Capital Partners, an estimated $9.64M added.
  • The largest BioCryst Pharmaceuticals seller in Q1 2020 was Point72 Asset Management, an estimated $14.8M sold.

Based on aggregated 13F filings for Q1 2020.